ArticleNeurocritical care2026
Albumin-Anchored Thromboinflammatory Ratios Provide Modest Incremental Prognostic Value Beyond Clinical Severity Scores in Aneurysmal Subarachnoid Hemorrhage: A Retrospective Study.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAneurysmal subarachnoid hemorrhage (aSAH) remains associated with substantial mortality and functional disability despite advances in neurosurgical and intensive care management. Systemic inflammation and thromboinflammatory activation play key roles in early brain injury and secondary complications. We aimed to evaluate the prognostic value of albumin-anchored inflammatory ratios-C-reactive protein/Albumin ratio (CAR) and D-dimer-to-Albumin Ratio (DAR)-for predicting functional outcome and in-hospital mortality in patients with aSAH. MATERIALS AND
methodsIn this retrospective multicenter cohort study, 212 adult patients with radiologically confirmed aSAH were included. Admission laboratory parameters obtained within the first 24 h were analyzed. The primary outcome was poor functional status at discharge (modified Rankin Scale [mRS] ≥ 3); the secondary outcome was in-hospital mortality. Univariable and multivariable logistic regression analyses were performed. Discriminatory performance was evaluated using receiver operating characteristic (ROC) analysis, and incremental prognostic value was assessed through model comparison, calibration analysis, and decision curve analysis.
resultsPoor functional outcome occurred in 88 patients (41.5%), and in-hospital mortality was observed in 36 patients (17.0%). Both CAR and DAR were significantly higher in patients with poor outcomes (p < 0.001 for both). In multivariable analysis, DAR (adjusted OR 1.89, 95% CI 1.32-2.71, p < 0.001) and CAR (adjusted OR 1.11, 95% CI 1.04-1.18, p = 0.002) independently predicted poor functional outcome. ROC analysis demonstrated AUC values of 0.83 (95% CI 0.77-0.89) for CAR and 0.86 (95% CI 0.80-0.91) for DAR. For mortality prediction, DAR achieved an AUC of 0.90 (95% CI 0.85-0.95). The addition of DAR to a clinical model (age, GCS, Hunt-Hess grade) provided a modest but statistically significant improvement in discrimination for poor outcome (AUC increase from 0.89 to 0.92; p = 0.028) and mortality (AUC increase from 0.91 to 0.94; p = 0.031). Reclassification analyses showed a continuous NRI of 0.21 (95% CI 0.05-0.37; p = 0.012) and an IDI of 0.028 (95% CI 0.006-0.050; p = 0.018).
conclusionsAlbumin-anchored inflammatory ratios, particularly DAR, were independently associated with poor functional outcome and in-hospital mortality in patients with aSAH. DAR provides modest incremental prognostic information beyond established clinical severity scores, supported by improvements in reclassification metrics; however, its clinical impact should be interpreted cautiously.
Indexed as
Identifiers
42557436What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.